IPO

With a new SPAC filing, NorthStrive leverages deep advisory expertise to target aerospace and defense, signaling a strategic play in a disciplined market.

A new $75 million SPAC has hit the market, but this isn't just another Wall Street vehicle. It's a high-stakes search for the next technology titan.

A Tokyo innovator just hit Nasdaq via a SPAC. Is its vertically integrated model the key to unlocking the $67B longevity market or just another biotech gamble?

As Lyntris files for its IPO under the ticker 'LYNX', it's more than a public offering; it's a test of market appetite for the future of connected warfare.

Brazilian Rare Earths' massive discovery and savvy corporate split could be a game-changer for tech supply chains. But can it navigate the path to production?

B&R Technology Merger Corp. just raised $325M. With a veteran tech team at the helm, their IPO isn't just another blank check—it's a calculated bet.

Bob Ritchie's 'Thought Leader of the Year' award isn't just a trophy. It's a nod to his bold strategy that tamed Florida's chaotic insurance market.

Stewards Inc. celebrates a key SEC approval for its Nasdaq ambitions, but a closer look reveals the company is in a race to build its foundation before it can reach the summit.

A company born from Celsius Mining's bankruptcy is skipping the IPO hype to directly list on Nasdaq, betting its massive power grid can solve AI's biggest bottleneck.

With a massive IPO and backing from Agnico Eagle, Cadillac Mines is not just raising capital; it's signaling a major shift in Canada's mining landscape.

With its direct listing, QumulusAI isn't just going public; it's signaling a strategic maneuver to solve the AI compute crisis outside the hyperscaler shadow.

Cypriot banktech Xryma Plc is listing on Euronext Paris without raising a cent. We explore the strategy behind this unconventional move and its deep infrastructure play.

Following SK Hynix's record-breaking Nasdaq listing, new leveraged ETFs offer a way to bet big on the AI chip giant. But are these tools for traders or traps for the unwary?

A C$11.5 million deal for a company you've never heard of is set to accelerate the takeover of independent pharmacies. Is it a lifeline or the end of an era?

A small biotech is raising millions with a high-risk funding plan to launch a BOTOX alternative. Can it survive long enough to disrupt a pharma titan?

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

Rithm Property Trust is raising cash to buy multifamily loans from its own manager. Is this a savvy move in a tough market or a risky inside deal?

Amid a disciplined SPAC market resurgence, Samos Energy's new fund targets cash-generating assets, signaling a strategic pivot back to energy security.

NUBURU is launching a bold, premium-priced $38M offering to acquire Tekne, clear its books, and secure its NYSE listing in a high-stakes pivot to defense.